Testing an antibody drug for relapsed or hard-to-treat AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies a drug called CLAG-GO (an antibody with chemotherapy drugs attached) in adults with AML that has come back or did not respond to treatment. It aims to improve outcomes for people whose leukemia is persistent, relapsed, or refractory.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18+) with AML, but not acute promyelocytic leukemia (APL)
- Your AML is relapsed or did not respond after at least one intensive chemotherapy treatment
- Your leukemia cells have enough CD33 (at least 20%) on lab testing
- Your kidneys and liver are working well enough for treatment
- You can come to visits and follow the study plan (and have a clinician score of 0–2 for daily functioning)
- You do not have certain medicines or health conditions that would block the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This trial studies whether combining two medicines—midostaurin and gemtuzumab (with standard chemotherapy)—can improve outcomes for newly diagnosed acute myeloid leukemia (AML). It is testing a first-line treatment plan tailored to specific genetic changes in the leukemia.
This trial tests whether adding venetoclax to a standard chemotherapy regimen (CLAG) works better than the chemotherapy alone for adults whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This Phase 3 trial tests whether adding gemtuzumab to standard chemotherapy helps people with newly diagnosed, favorable-intermediate AML reduce “MRD” (very small remaining leukemia cells). If MRD levels drop more, it may lower the chance of relapse.
Hear when a new Acute Myeloid Leukemia, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.